UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stake in Thermo Fisher Scientific Inc. $TMO

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,428,731 shares of the medical research company's stock after buying an additional 13,728 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.65% of Thermo Fisher Scientific worth $1,407,328,000 as of its most recent filing with the Securities & Exchange Commission.The Market Is Selling Everything, but These 5 Stocks Aren't Breaking DownA number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TMO. Vanguard Group Inc. raised its holdings in Thermo Fisher Scientific by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock worth $19,778,774,000 after purchasing an additional 288,296 shares in the last quarter. Capital World Investors raised its holdings in Thermo Fisher Scientific by 7.0% in the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company's stock worth $6,376,229,000 after purchasing an additional 718,669 shares in the last quarter. Geode Capital Management LLC raised its holdings in Thermo Fisher Scientific by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company's stock worth $4,728,129,000 after purchasing an additional 26,425 shares in the last quarter. Franklin Resources Inc. raised its holdings in Thermo Fisher Scientific by 7.1% in the 4th quarter. Franklin Resources Inc. now owns 6,346,512 shares of the medical research company's stock worth $3,677,486,000 after purchasing an additional 420,841 shares in the last quarter. Finally, Norges Bank bought a new position in Thermo Fisher Scientific in the 4th quarter worth $3,072,744,000. 89.23% of the stock is currently owned by institutional investors. Thermo Fisher Scientific Price PerformanceShares of NYSE:TMO opened at $468.80 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The company has a market capitalization of $174.22 billion, a P/E ratio of 25.77, a P/E/G ratio of 2.11 and a beta of 0.88. The firm's 50 day simple moving average is $479.14 and its two-hundred day simple moving average is $527.68. The Often-Missed Corner of Healthcare That Wall Street Is LovingThermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same quarter in the previous year, the firm earned $5.15 earnings per share. The company's revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year. Thermo Fisher Scientific Announces DividendThe company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 10.34%. Insiders Place Their BetsSector Rotation: 2 Smart Money Moves for 2026In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares of the company's stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders. Wall Street Analyst Weigh InSeveral research analysts recently issued reports on TMO shares. Morgan Stanley reiterated an "overweight" rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 price objective for the company. DZ Bank started coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They set a "buy" rating and a $610.00 price target on the stock. Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a report on Friday, April 24th. Finally, Barclays dropped their price target on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating on the stock in a report on Tuesday, April 14th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $608.95.Check Out Our Latest Analysis on Thermo Fisher ScientificAbout Thermo Fisher Scientific (Free Report)Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently. Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.Featured StoriesFive stocks we like better than Thermo Fisher ScientificSpaceX Rings the Bell and Shatters Every RecordAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?3 Dividend Stocks Under $50 That Pay You to Wait Out InflationThe 127-Gigawatt Problem: Why AI Needs Its Own PowerWant to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Thermo Fisher Scientific Right Now?Before you consider Thermo Fisher Scientific, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here